Momenta Pharmaceuticals appoints Dr Jose-Carlos Gutierrez-Ramos to its Board of Directors

– USA, MA – Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Jose-Carlos (JC) Gutiérrez-Ramos, Ph.D. to its Board of Directors effective March 9, 2016. Dr. Gutiérrez-Ramos currently serves as Chief Executive Officer and President of Synlogic Inc. and was previously Group Senior Vice President and Global Head of BioTherapeutics Research and Development at Pfizer.

“JC is a very welcome addition to our Board and brings more than twenty years of valuable drug research and development experience from leading global biopharmaceutical companies,” said Craig Wheeler, President and CEO, Momenta Pharmaceuticals. “JC’s deep scientific knowledge in immunology and oncology and broad expertise in biologics production and clinical drug development will be invaluable to the Company as we advance our biosimilar and novel drug candidates through development and toward commercialization.”

Dr. Gutiérrez-Ramos has served as Chief Executive Officer and President of Synlogic Inc., since May 2015. Previously, he served as Group Senior Vice President and global head of the BioTherapeutics Research at Pfizer where he was responsible for more than 25 novel programs across the full spectrum of clinical development, re-launched efforts in Rare Disease Discovery and Development and founded the Centers for Therapeutic Innovation. He also oversaw and enhanced the biologics platform for the company from early discovery to entry in manufacturing. Dr. Gutiérrez-Ramos was previously Senior Vice President and Head of the Immuno-inflammation Center for Drug Discovery (iiCEDD) at GSK, where he founded entrepreneurial units such as Epinova and Tempero focused in translating novel areas of science (Epigenetics, Tregs, etc) into therapeutics. Prior to his work in the pharmaceutical industry, Dr. Gutiérrez-Ramos held senior leadership positions at several biotech companies, including Senior Vice President and Head of R&D at Avidia Inc. and Peptimmune Inc. He began his career in the drug industry at Millennium Pharmaceuticals serving as Vice President of Inflammation Drug Discovery. Dr. Gutiérrez-Ramos holds a Ph.D. in immunochemistry from the Autonoma University in Madrid, Spain.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.

- DisclaimerNews, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>

Comments are closed.